Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
NCT00106054
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- ECOG performance status of 0 or 1
- Histological documentation of adenocarcinoma of the colon or rectum. The primary site must have been confirmed to be in the large bowel
- Prior systemic anticancer therapy for mCRC
- Prior hepatic surgery, chemoembolization, hepatic artery infusion, radiofrequency
ablation or cryotherapy for liver metastases
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Gent,
- Roeselare,
- Copenhagen,
- Herlev,
- Odense,
- Amiens cedex 1,
- Avignon,
- Boulogne Billancourt cedex,
- Clermont-Ferand Cedex 1,
- Colmar,
- Grenoble Cedex 09,
- Marseille Cedex 9,
- Marseille,
- Marseille,
- Montpellier Cedex 5,
- Montpellier,
- Nice,
- Nimes,
- Rennes,
- Strasbourg,
- Toulouse cedex,
- Cottbus,
- Dessau,
- Erlangen,
- Hamburg,
- Leipzig,
- Magdeburg,
- Magdeburg,
- Mainz,
- Oldenburg,
- Regensburg,
- Tuebingen,
- Hong Kong,
- Haifa,
- Petach-Tikva,
- Rehovot,
- Tel-Aviv,
- Tel-Hashomer,
- Carpi, Modena
- Brescia,
- Latisana, UD,
- Padova,
- Parma,
- Piacenza,
- Reggio Emilia,
- Rozzano (Mi),
- Daegu,
- Goyang,
- Seoul,
- Seoul,
- Seoul,
- Porto,
- Panorama, Cape Town
- L'Hospitalet de Llobregat, Barcelona
- Santander, Cantabria
- Barcelona,
- Madrid,
- Sevilla,
- Goteborg,
- Bern,
- Taoyuan,
- Donetsk,
- Kiev,
- London,
- Southampton,
- Surrey,
- New York, New York
- Philadelphia, Pennsylvania
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases | |||
| Official Title ICMJE | An Open-Label, Multi-Center Phase II Trial of Neoadjuvant Irinotecan in Combination With Infusional 5-FU, Leucovorin (Folfiri) Plus Bevacizumab in Patients With Unresectable Hepatic-Only Metastases of Colorectal Carcinoma | |||
| Brief Summary | The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be performed. This trial is studying the effects (good and bad) of a combination of drugs, Irinotecan in combination with infusional 5-FU, leucovorin (FOLFIFI) plus Bevacizumab, for cancer of the colon or rectum that has spread to the liver only and is currently not able to be removed by surgery. All of the drugs that will be received in this research study have been approved in the United States for colorectal cancer, that has spread to other areas of the body, including the liver. Another reason for doing this study is to see if the chemotherapy drugs FOLFIFI plus Bevacizumab can sufficiently decrease the size of the cancer in the liver so that any tumor remaining can be completely removed with surgery and, if it can be removed whether doing so will prolong the time it takes the cancer to return and/or prolong the life of these patients. This trial is also looking at the genes of people who take part in this study, to see if it is possible to find out characteristics that can help predict whose cancer will respond well or not so well, and who will have more or less side effects to this chemotherapy. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 2 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE |
| |||
| Intervention ICMJE | Drug: Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting. | |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Terminated | |||
| Actual Enrollment ICMJE | 2 | |||
| Original Enrollment ICMJE | Not Provided | |||
| Actual Study Completion Date ICMJE | September 2006 | |||
| Actual Primary Completion Date | September 2006 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00106054 | |||
| Other Study ID Numbers ICMJE | A5961065 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | August 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||